Citations

Clear

6 citation(s) found for "Martin, Austin".

Impact of Artificial Urinary Sphincter Placement on Quality of Life: A Validated Outcome Assessment
Martin, Austin , Linder, Brian J. , O’Byrne, Jamie, Elliott, Daniel S. , O'Byrne, Jamie J, Linder, Brian J

Mayo Clinic

Neurourology and Urodynamics | April 17, 2025 | Volume: 44 | Issue: 5 | Pages: 1134-1139

10.1002/nau.70056 | PMID 40241496 Get It

ABSTRACTIntroductionArtificial Urinary Sphincter (AUS) placement is the preferred treatment for moderate to severe incontinence following prostate cancer treatment. While device related outcomes related to device survival are well reported, literature on quality‐of‐life outcomes, including the use of validated measures is limited.MethodsWe queried a prospectively maintained database of male patients undergoing primary AUS implantation from 2015 to 2023 at our institution. All patients completed a preoperative Michigan Incontinence Symptom Index (M‐ISI) and Patient Global Impression of Improvement (PGI‐I). Postoperative quality of life data was obtained by mailed correspondence. Surveys obtained following AUS reoperation/revision were excluded. Pairwise comparisons were performed between preoperative functional status and the Postoperative responses. Logistic regression analysis was performed to identify preoperative variables associated with a favorable PGI‐I score defined as “very much better or much better,” or a decrease in pad usage from > 1 pad per day to ≤ 1 pad per day.ResultsDuring the study timeframe, 383 patients underwent primary AUS placement, of which 163 patients (42%) completed a postoperative survey and were included in the study. Median age was 69.0 (IQR: 64–74) and 54.6% of patients had a history of pelvic radiation. The median time from surgery to the postoperative survey was 2.2 years (IQR: 0.9, 4.3). Compared to baseline, following AUS placement there was a significant improvement in the total M‐ISI score (10 [6, 16) vs 26 [22, 30]; p < 0.0001) (Minimally Important Difference = 4). This included improvements in the SUI subscore [4 (IQR 2, 6) vs 10 (IQR: 9, 12); p < 0.0001] and bother score [1 (IQR: 0, 3) vs 6 (IQR: 5, 7); p < 0.001)]. Pad usage significantly decreased following device placement (p < 0.0001). The vast majority of patients (90.7%) would “definitely or probably recommend to a friend/family member.” On univariable analysis, active smoking (ref. never) was associated with adverse pad use outcomes (OR: 0.1, 95% CI: 0–0.8; p = 0.03) and older age was associated with adverse PGI‐I outcome (OR: 0.93, 95% CI: 0.87–0.99; p = 0.02).ConclusionsFollowing AUS implantation, most patients have significant improvement in validated quality of life outcomes and low pad usage. These findings persist despite multiple preoperative comorbidities and should be considered when counseling patients before AUS placement.
Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma
Yu, Alice , Martin, Austin , Potrezke, Aaron, Pham, Jonathan , Pallauf, Maximilian , Singla, Nirmish, Katims, Andrew , Margulis, Vitaly , Pallauf, Maximilian , Margulis, Vitaly , Matin, Surena F. , Hensley, Patrick J. , Huelster, Heather L. , Pham, Jonathan, Raman, Jay D. , Coleman, Jonathan , Spiess, Philippe E.

Mayo Clinic

BJU International | January 18, 2025 | Volume: 135 | Issue: 6 | Pages: 994-999

10.1111/bju.16655 | PMID 39825642 Get It

Objectives To evaluate the benefit of neoadjuvant chemotherapy (NAC) for patients with high‐risk upper tract urothelial carcinoma (UTUC) using a large, well‐curated multi‐institutional database. Patients and Methods This study was a multi‐institutional retrospective analysis conducted by the UTUC Collaborative Network (UCAN), combining data from 2276 patients with UTUC who underwent radical nephroureterectomy at seven high‐volume tertiary care centres in the United States. The UCAN data were analysed to evaluate the impact of response to NAC on survival outcomes in patients with UTUC. Results A total of 378 patients in the UCAN database underwent NAC. On final surgical pathology, 101 patients (26.8%) had ≤ypT1N0 disease and were defined as NAC treatment responders. Patients who responded to NAC had significantly longer overall survival (OS) and progression‐free survival (PFS) compared to non‐responders. At 5 years post‐surgery, 81.5% of responders were alive compared to 59.8% of non‐responders. The median OS and PFS times among non‐responders were 7.0 years (95% confidence interval [CI] 5.6–9.7) and 6.0 years (95% CI 4.6–9.3) respectively, while the median OS and PFS were not reached among responders. Limitations of this study include its retrospective design, heterogeneity in chemotherapy regimens, and the absence of clearly defined patient selection criteria for treatment. Conclusion These data suggest that NAC can play a pivotal role in the treatment of well‐selected UTUC patients who respond positively. Non‐responders had clearly inferior outcomes. More work is needed to find predictors of response which can improve patient selection.
In‐field prostate cancer recurrence following radical prostatectomy and salvage radiation
Martin, Austin , Britton, Cameron J. , Fadel, Anthony , Ahmed, Mohamed E., Sharma, Vidit , Mynderse, Lance A. , Lomas, Derek J. , Woodrum, David A. , Frendl, Daniel M. , Karnes, Jeffrey , Tollefson, Matthew K. , Kwon, Eugene D., Andrews, Jack R. , Fadel, Anthony , Davis, Brian J. , Mynderse, Lance, Lomas, Derek , Woodrum, David, Karnes, Jeffrey R, Mahmoud, Ahmed , Childs, Daniel S. , Johnson, Geoffrey B.

Mayo Clinic

BJU International | November 30, 2024 | Volume: 135 | Issue: 4 | Pages: 668-674

10.1111/bju.16598 | PMID 39614716 Get It

Objective To define the natural history, patterns of recurrence and treatment modalities for local prostate cancer (PCa) recurrence following radical prostatectomy (RP) and radiation therapy (RT), and to investigate factors that could predict metastasis‐free survival (MFS) in this unique patient population. Methods We queried a prospectively maintained PCa registry to identify men developing in‐field recurrence (IFR) following RP and RT from 2008 to 2021 at a single institution. IFR was defined as biopsy‐proven recurrent PCa or the presence of persistent positron emission tomography‐avid lesions in the prior radiation field without evidence of metastasis. Cox regression was conducted to determine predictors of MFS. Kaplan–Meier methods were used to calculate MFS, cancer‐specific survival (CSS) and overall survival (OS) for patients in three primary therapy categories: cryoablation, androgen deprivation therapy (ADT) alone, and surveillance. Results Of 4575 patients from our registry, 108 (2.3%) with IFR were identified. The median (interquartile range [IQR]) time to IFR from salvage treatment was 78 (50–126) months. A total of 29 patients (26%) were managed with cryoablation, 23 (21%) with ADT, and 28 (25%) with surveillance. The median (IQR) follow‐up was 76 (48–100) months. There were no statistically significant differences in MFS ( P = 0.67) or OS ( P = 0.07) among the three primary treatment cohorts. Patients treated with ADT or cryoablation had longer CSS compared to patients managed with surveillance ( P = 0.047). Conclusions We found that IFR may present years after completion of primary treatment for PCa. While curative management strategies may be attempted, local and distant metastatic recurrence is common and often requires systemic therapy.
Reply to Editorial Comment: Erector Spinae Plane Block Reduces Postoperative Pain and Narcotic Utilization Compared With Transversus Abdominis Plane Block After Cystectomy With Urinary Diversion
Igel, Daniel A. , Martin, Austin J. , Wyre, Hadley, Mirza, Moben, Holzbeierlein, Jeffrey M., Thompson, Jeffrey , Pozek, John-Paul J., Lee, Eugene K. , Sullivan, Peter, Taylor, John A.

Mayo Clinic

JU Open Plus | August 16, 2024 | Volume: 2 | Issue: 8 | Pages: No page available

10.1097/ju9.0000000000000182 Get It

Erector Spinae Plane Block Reduces Postoperative Pain and Narcotic Utilization Compared With Transversus Abdominis Plane Block After Cystectomy With Urinary Diversion
Igel, Daniel A. , Martin, Austin J. , Wyre, Hadley, Mirza, Moben, Holzbeierlein, Jeffrey M., Thompson, Jeffrey , Pozek, John-Paul J., Lee, Eugene K. , Sullivan, Peter, Taylor, John A.

Mayo Clinic

JU Open Plus | August 16, 2024 | Volume: 2 | Issue: 8 | Pages: No page available

10.1097/ju9.0000000000000170 Get It

Background: Regional analgesia is a critical component of enhanced recovery after surgery pathways for cystectomy, but there is little research comparing different modalities. Transversus abdominis plane block is a well-established procedure used for postoperative regional analgesia, whereas erector spinae plane block is a recently described technique that some contend improves pain control. Objective: We sought to compare these modalities in patients undergoing cystectomy, with primary end points of pain scores and total narcotic utilization measured in morphine milliequivalents. Methods: We retrospectively reviewed 77 consecutive patients who underwent open radical cystectomy. Patients who did not undergo erector spinae plane block or transversus abdominis plane block or who used chronic narcotics were excluded. Pain intensity scores were measured immediately postoperatively and in 24-hour intervals until 72 hours postoperatively. Cumulative narcotic utilization at 72 hours, return to bowel function, and length of stay were measured. Results: Fifty-one patients met inclusion criteria. Seventeen patients underwent erector spinae plane block and 34 transversus abdominis plane block. Erector spinae plane block patients reported lower pain scores immediately postoperatively (P = .046), at 48 hours (P = .019), and 72 hours (P = .019). Erector spinae plane block patients used less narcotics after 72 hours than transversus abdominis plane block patients (median: 62.50 morphine milliequivalents vs 146.25 morphine milliequivalents, P = .008). Conclusions: Compared with transversus abdominis plane block, erector spinae plane block reduced total narcotic utilization by 234% while also reducing subjective patient pain scores. Increased adoption of erector spinae plane block could have major impacts on both clinical outcomes and patient satisfaction in patients undergoing radical cystectomy.
Role of MIF1 / MIF2 / CD74 interactions in bladder cancer
Woolbright, Benjamin L. , Rajendran, Ganeshkumar, Abbott, Erika, Martin, Austin, Amalraj, Sarah, Dennis, Katie , Warrick, Joshua, Li, Xiaogang , Taylor, John Arthur

Mayo Clinic

The Journal of Pathology | October 10, 2022 | Volume: 259 | Issue: 1 | Pages: 46-55

10.1002/path.6018 | PMID 36214539 Get It

Abstract Macrophage migration inhibitory factor (MIF1) is a pleiotropic cytokine involved in inflammation and cancer. Genetic knockout of Mif1 in the validated N ‐butyl‐ N ‐(4‐hydroxybutyl) nitrosamine (BBN) model of bladder cancer (BCa) resulted in stage arrest at non‐muscle‐invasive disease in prior studies. Small‐molecule inhibition of MIF1 reduced cancer‐associated outcomes, but it did not fully recapitulate genetic models. D‐dopachrome tautomerase (gene symbol DDT ), commonly referred to as MIF2, is a functional homolog of MIF1, and both MIF1 and MIF2 can bind the cell surface receptor CD74 on multiple cell types to initiate a signaling cascade. It has been proposed that this interaction mediates part of the protumorigenic effects of MIF1 and MIF2 and may explain the discordance in prior studies. We hypothesized that MIF2 functions redundantly with MIF1 in BCa development and progression. The Cancer Genome Atlas (TCGA) analysis indicated MIF and DDT expression were increased in BCa patients compared to control. 4‐Iodopyridine (4‐IPP), a combined MIF1/MIF2 inhibitor, was more efficacious than ISO‐1, a MIF1‐only inhibitor, in preventing cellular proliferation in BCa cell lines. To evaluate these findings in vivo , wild‐type (WT) and Mif1 −/− animals were exposed to 0.05% BBN in drinking water for 16 weeks to initiate tumorigenesis and then evaluated over the subsequent 4 weeks for tumor formation and progression in the presence or absence of 4‐IPP. 4‐IPP reduced bladder weights in WT animals and bladder weights/tumor stage in Mif1 −/− animals. To determine whether MIF1/MIF2 functioned through CD74 in BCa, WT or Cd74 −/− animals were used in the same BBN model. Although these animals were partially protected against BBN‐induced BCa, 4‐IPP did not enhance this effect. In conclusion, our data suggest that MIF2 mechanistically functions in a similar protumorigenic manner to MIF1, and this is at least partially through CD74. Dual inhibition of MIF homologs is more efficacious at reducing tumor burden in this model of BCa. © 2022 The Pathological Society of Great Britain and Ireland.